Literature DB >> 8936563

Itraconazole increases serum digoxin concentration.

J Partanen1, K M Jalava, P J Neuvonen.   

Abstract

Itraconazole can interact with several drugs by inhibiting their metabolism. Many drugs known to increase serum digoxin concentration are inhibitors of CYP enzymes (e.g. verapamil, diltiazem, amiodarone, cyclosporine). Case reports suggest that itraconazole, added to digoxin therapy, may induce digoxin intoxications; hence we wanted to study their possible interaction. In this two-phase study ten healthy young volunteers ingested 0.25 mg of digoxin daily for 20 days. Concomitantly, they received either 200 mg itraconazole or placebo orally once daily for 10 days in a double-blind, randomized, cross-over study design. Serum concentrations of digoxin and itraconazole were measured (12 hr after administration) on days 1, 2, 4, 6, 8, 10, 11, 12, 14, 16, 18 and 20. Digoxin concentrations were measured by fluorescence polarization immunoassay and confirmed (days 10 and 20) by affinity column-mediated immunoassay. Itraconazole increased serum digoxin concentration in each of the subjects. On the 10th day of the placebo phase serum digoxin concentration was 1.0 +/- 0.1 nmol/l, and on the 10th day of the itraconazole phase 1.8 +/- 0.1 nmol/l (P < 0.001). Care should be taken if itraconazole is prescribed to patients using digoxin. The mechanism of the itraconazole-digoxin interaction is unclear but may be related to CYP3A4-mediated changes in the pharmacokinetics of digoxin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8936563     DOI: 10.1111/j.1600-0773.1996.tb00273.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  14 in total

1.  Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions.

Authors:  Kim R Saverno; Lisa E Hines; Terri L Warholak; Amy J Grizzle; Lauren Babits; Courtney Clark; Ann M Taylor; Daniel C Malone
Journal:  J Am Med Inform Assoc       Date:  2010-12-03       Impact factor: 4.497

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; C Lindsay DeVane
Journal:  Psychopharmacology (Berl)       Date:  2006-06-30       Impact factor: 4.530

4.  Use of different parameters and equations for calculation of IC₅₀ values in efflux assays: potential sources of variability in IC₅₀ determination.

Authors:  Donna A Volpe; Salaheldin S Hamed; Lei K Zhang
Journal:  AAPS J       Date:  2013-12-13       Impact factor: 4.009

Review 5.  Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Authors:  David J Greenblatt; Jerold S Harmatz
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

6.  Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.

Authors:  Nora M Hagelberg; Tuukka Saarikoski; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Miia Turpeinen; Mika Scheinin; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-10-26       Impact factor: 2.953

Review 7.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

8.  Rifampicin reduces plasma concentrations of celiprolol.

Authors:  J J Lilja; M Niemi; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2003-11-12       Impact factor: 2.953

9.  Voriconazole does not affect the steady-state pharmacokinetics of digoxin.

Authors:  Lynn Purkins; Nolan Wood; Diane Kleinermans; Don Nichols
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

10.  Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.

Authors:  Vincent J C Lempers; Jeroen J M W van den Heuvel; Frans G M Russel; Rob E Aarnoutse; David M Burger; Roger J Brüggemann; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.